The development of anticyclic citrullinated peptide (anti‐CCP) antibody following severe COVID‐19

• Published in: Immunity, Inflammation and Disease Vol. 12; no. 5; pp. e1276 - n/a
• Main Authors: Roghani, Seyed Askar, Dastbaz, Mohammad, Lotfi, Ramin, Shamsi, Afsaneh, Abdan, Zahra, Rostampour, Rezvan, Soleymani, Bijan, Zamanian, Mohammad Hossein, Soufivand, Parviz, Pournazari, Mehran, Taghadosi, Mahdi
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.05.2024; John Wiley and Sons Inc; Wiley
• Subjects: Adult; Aged; Anti-Citrullinated Protein Antibodies - blood; Anti-Citrullinated Protein Antibodies - immunology; Antibodies; Antibodies, Antinuclear - blood; Antibodies, Antinuclear - immunology; anti‐CCP; autoantibodies (AABs); Autoantibodies - blood; Autoantibodies - immunology; Autoimmune diseases; Autoimmune Diseases - blood; Autoimmune Diseases - immunology; autoimmunity; Coronaviruses; Correlation analysis; COVID-19; COVID-19 - blood; COVID-19 - immunology; Female; Humans; Immunoglobulins; Lupus; Male; Middle Aged; Neutrophils; Original; Patients; Peptides; Rheumatic diseases; Rheumatic Diseases - blood; Rheumatic Diseases - immunology; Rheumatoid arthritis; SARS-CoV-2 - immunology; SARS‐CoV‐2; Sea level; Severity of Illness Index; Iran; autoantibodies (AABs); COVID‐19; autoimmunity; SARS‐CoV‐2; anti‐CCP

Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a modera...